Melanoma Therapeutics Market 2020 - Industry Analysis and Forecast by Radiant Insights, Inc.
Summary Radiant Insights, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth" Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas. Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth. Access This Full Report @ http://www.radiantinsights.com/research/melanoma-therapeutics-market-to-2020-rising-prevalence-and-evolving-treatment-algorithms-to-drive-market-growth Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.
Summary
Radiant Insights, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth"
Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas.
Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.
Access This Full Report @ http://www.radiantinsights.com/research/melanoma-therapeutics-market-to-2020-rising-prevalence-and-evolving-treatment-algorithms-to-drive-market-growth
Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
3.3 Therapy for Advanced (Unresectable or Metastatic) <strong>Melanoma</strong> 52<br />
3.3.1 Chemotherapy 52<br />
3.3.2 Immunotherapy 54<br />
3.3.3 Targeted Therapies 59<br />
3.4 Heat Maps for <strong>Market</strong>ed Products 62<br />
4 <strong>Melanoma</strong> Pipeline 68<br />
4.1 Overview 68<br />
4.2 Pipeline Distribution <strong>by</strong> Phase of Development, Molecule Type, Route of Administration <strong>and</strong> Novelty<br />
70<br />
4.3 Pipeline Distribution <strong>by</strong> Molecular Target 76<br />
4.4 Clinical Trial L<strong>and</strong>scape 82<br />
Access This Full Report @ http://www.radiantinsights.com/research/melanoma-therapeuticsmarket-to-<strong>2020</strong>-rising-prevalence-<strong>and</strong>-evolving-treatment-algorithms-to-drive-market-growth<br />
4.4.1 Clinical Trial Failure Rates 82<br />
4.4.2 Clinical Trial Duration 86<br />
4.4.3 Clinical Trial Size 89<br />
4.4.4 Primary <strong>and</strong> Secondary Endpoints 91<br />
4.5 Promising Pipeline Molecules 97<br />
4.5.1 Adjuvant Immunotherapy 97<br />
4.5.2 Advanced Disease Immunotherapy 101<br />
4.5.3 Advanced Disease Targeted Therapy 103<br />
4.6 Heat Map <strong>and</strong> Competitor Matrix for Pipeline Products 110<br />
5 <strong>Market</strong> <strong>Forecast</strong> to <strong>2020</strong> 117<br />
5.1 Geographical <strong>Market</strong>s 117
Change language